stockrow
Saturday 7 November 2026
Export TVGN’s income statement to Excel — free account
Tevogen Inc.
TVGN Healthcare Biotechnology
- EPS
- +11.1%
- Free cash flow
- +5.78%
- Total debt
- +45.5%
Quarter to June 2026, against a year earlier
5.35
0.21
−3.78%
Follow TVGN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 123.10% | 124.81% | 165.04% | 207.28% |
+8 more TTM periods Free account |
|
| (492.20%) | (487.93%) | (683.91%) | (698.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
549.21% | 439.95% | 500.62% | 689.47% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.02) | (3.37) | (3.73) | (3.37) | |
Free Cash Flow |
(11.57) | (11.75) | (12.39) | (13.19) | |
Capital Expenditures |
— | — | (0.06) | — | |
| Other line items | |||||
Cash ROIC |
822.55% | 427.44% | 377.57% | 552.83% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(70.73) | (87.47) | (133.64) | (219.57) | |
Operating CF/Net income |
0.52 | 0.54 | 0.46 | 0.43 | |
Depreciation/Fixed assets |
2.11 | 3.31 | 2.99 | 3.22 | |
Capex/Depreciation |
0.00 | 0.00 | (0.13) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.02) | (3.37) | (3.71) | (3.37) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026